Related Experiment Video

Updated: Jul 1, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in

Yaling Jiang1, Nong Lin1,2,3,4, Xin Huang1

  • 1Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Future Oncology (London, England)
|June 30, 2026
PubMed

Insights

This study investigates vebreltinib plus PD-1 immunotherapy for advanced clear cell sarcoma (CCS). The combination targets MET and PD-1 pathways, potentially offering a new treatment for this rare cancer.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Clear cell sarcoma (CCS) is a rare cancer lacking effective standard systemic therapies.
  • Mesenchymal-epithelial transition factor (MET) overexpression is a key driver of CCS progression.
  • MET inhibitors like vebreltinib show therapeutic promise for CCS.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining vebreltinib with PD-1-based immunotherapy in advanced CCS.
  • To explore the combined inhibition of MET and PD-1 pathways in CCS treatment.
  • To provide evidence for novel therapeutic strategies in advanced CCS management.

Main Methods:

  • A multicenter, phase II clinical trial (VEBrant study, NCT07153887) enrolling 30 patients with advanced CCS.
  • Treatment cohort: vebreltinib plus PD-1 inhibitor.
  • Reference cohort: physician's choice therapy or best supportive care.
  • Primary endpoint: Objective Response Rate (ORR) using a Simon two-stage design.

Main Results:

  • This section will report the Objective Response Rate (ORR) and safety profile of the combination therapy.
  • Analysis will compare outcomes between the treatment and reference cohorts.
  • Results will elucidate the clinical benefit of vebreltinib and PD-1 inhibitor combination in advanced CCS.

Conclusions:

  • The VEBrant study aims to establish vebreltinib plus PD-1 immunotherapy as a potential treatment for advanced CCS.
  • Findings will enhance understanding of MET and PD-1 pathway interactions in CCS.
  • This research may lead to improved therapeutic options for patients with advanced clear cell sarcoma.
Keywords:
MET inhibitorPD-1clear cell sarcomaimmunotherapyvebreltinib

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...